Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyViva Health Tecentriq Coverage & Prior Auth | Open…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0278

    Tecentriq (atezolizumab) — Coverage and Authorization Policy

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0278 alerts

    Get alerted when Policy IC-0278 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, length of authorization, and clinical coverage criteria for intravenous atezolizumab (Tecentriq) for Viva Health members across multiple cancer indications.

    Policy Summary
    PayerViva Health
    PolicyTecentriq (atezolizumab) — Coverage and Authorization Policy
    Policy CodePolicy IC-0278
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial validity 6 months) and provide documentation showing indication-specific criteria, disease response, and absence of unacceptable toxicity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsinitial prior authorization validity
    504/84dmax billable units (most)
    120/21dmax billable units (meso/thymic/CLL)
    >=18minimum member age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J9022
    HCPCS code
    N/AMedicare Part B codes (excerpt)

    Coverage Criteria by Indication

    Peritoneal Mesothelioma (including pericardial & tunica vaginalis testis)

    Covered when the following are met:

    Peritoneal Mesothelioma coverage: Used as subsequent therapy in combination with bevacizumab

    May also be used for pericardial mesothelioma and tunica vaginalis testis mesothelioma

    Non‑Small Cell Lung Cancer (NSCLC)

    Covered when specific combinations of disease stage, line of therapy, performance status, biomarker status, and treatment combinations are met

    General NSCLC initial conditions: Used for recurrent, advanced, or metastatic disease; AND member is age >= 18; AND universal criteria are met
    First-line single-agent eligibility: Single-agent first-line for members with performance status (PS) 0-2 who have tumors negative for actionable biomarkers (may be KRAS G12C mutation positive) and PD-L1 ≥50% (TC≥50% or IC≥10%) as determined by an FDA-approved or CLIA-compliant test; OR members with PS 3 who have tumors negative for actionable biomarkers regardless of PD-L1; OR members with PS 3 who have tumors positive for EGFR exon 20, BRAF V600E, NTRK1/2/3 fusion, MET exon-14 skipping, ERBB2 (HER2), or NRG1 fusionPD-L1 per FDA-approved or CLIA-compliant test
    Combination first-line eligibility: Used in combination with carboplatin + paclitaxel + bevacizumab OR carboplatin + albumin-bound paclitaxel for non-squamous disease; tumor may be negative for actionable biomarkers (may be KRAS G12C positive) OR positive for EGFR exon 20, BRAF V600E, NTRK1/2/3 fusion, MET exon-14 skipping, ERBB2 (HER2), or NRG1 fusion

    Non-squamous histology required for listed combinations

    Subsequent therapy: Single-agent for members with PS 0-2 OR PS 3 with specified biomarker profiles per policy; combination options mirror first-line combinations for non-squamous disease
    Adjuvant therapy: Adjuvant single-agent use when tumor PD-L1 ≥1% as determined by an FDA-approved or CLIA-compliant test following resection and prior adjuvant platinum-based chemotherapy in specified stagesPD-L1 ≥1% per FDA-approved or CLIA-compliant test

    Stage and resection status requirements described in policy

    Small Cell Lung Cancer (SCLC)

    Covered when the following are met for extensive-stage disease

    SCLC criteria: Member has extensive-stage small cell lung cancer (ES-SCLC); AND used as first-line therapy in combination with carboplatin and etoposide OR used as maintenance therapy if disease has not progressed following first-line therapy with atezolizumab (intravenous or subcutaneous), carboplatin, and etoposide (maintenance may be single agent or used in combination with lurbinectedin); OR used as subsequent therapy for progression/relapse after a prolonged disease-free interval in combination with carboplatin and etoposide or as maintenance single agent or with lurbinectedin; AND member has at least stable disease following 4 cycles of subsequent therapy (when applicable); AND member has ECOG performance status 0-1; AND no history of brain metastases

    Member should have ECOG 0-1 and no history of brain metastases for some maintenance/subsequent settings

    Hepatocellular Carcinoma (HCC)

    Covered when used in combination with bevacizumab

    HCC indications: Used in combination with bevacizumab as first-line therapy for unresectable or metastatic hepatocellular carcinoma OR used as subsequent-line therapy after progression on or after systemic therapy

    Cutaneous Melanoma (BRAF V600 mutation‑positive)

    Covered when used in combination with BRAF/MEK targeted agents

    Melanoma criteria: Member has BRAF V600 mutation-positive cutaneous melanoma as detected by an FDA-approved or CLIA-compliant test; AND used in combination with cobimetinib and vemurafenib; AND member has unresectable or metastatic disease and is receiving first-line or subsequent therapy OR used as re-induction if prior BRAF/MEK + PD-(L)1 achieved disease control and progression occurred >3 months after discontinuation

    Alveolar Soft Part Sarcoma (ASPS)

    Covered when the following are met:

    ASPS criteria: Member is at least 2 years of age; AND used as a single agent

    Cervical Cancer (including small cell NECC and other histologies)

    Covered when used in appropriate combinations or maintenance settings

    Small cell NECC: Small cell neuroendocrine carcinoma of the cervix: used as first-line or subsequent therapy for persistent, recurrent, or metastatic disease in combination with etoposide and either cisplatin or carboplatin; OR used as single-agent maintenance after initial atezolizumab + etoposide + cisplatin/carboplatin
    Adeno/adenosquamous/squamous histologies: Adenocarcinoma, adenosquamous, or squamous cell carcinoma of the cervix: used as first-line or subsequent therapy for recurrent/metastatic disease in combination with bevacizumab + paclitaxel + (cisplatin or carboplatin); OR used in combination with bevacizumab as maintenance following initial atezolizumab + bevacizumab + paclitaxel + cisplatin/carboplatin

    Colorectal, Rectal, Small Bowel Adenocarcinoma (MSI-H/dMMR or POLE/POLD1 ultra-hypermutated)

    Covered for biomarker-defined tumors

    Colorectal colon adjuvant: Member has MSI-H/dMMR disease OR POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB >50 mut/Mb) as determined by an FDA-approved or CLIA-compliant test; AND used as adjuvant treatment in combination with FOLFOX or CAPEOX followed by single-agent maintenance therapy; AND member has stage IIC, stage III, or metastatic disease
    Colorectal single-agent advanced: Used as single agent for locally unresectable, medically inoperable, advanced, or metastatic colorectal disease with MSI-H/dMMR or POLE/POLD1 ultra-hypermutated status
    Rectal and small bowel: Member has MSI-H/dMMR disease OR POLE/POLD1 ultra-hypermutated phenotype as determined by an FDA-approved or CLIA-compliant test; AND used as single agent for locally unresectable, medically inoperable, advanced, or metastatic disease (small bowel: adjuvant FOLFOX/CAPEOX option for specified stages)

    Thymic Carcinoma (combination with chemotherapy)

    Covered when used with chemotherapy

    Thymic carcinoma criteria: Used in combination with carboplatin and paclitaxel; AND used as postoperative therapy after R1 or R2 resection OR used as first-line therapy for recurrent, advanced, or metastatic disease

    CLL/SLL (Richter transformation)

    Covered when used in combination with venetoclax and obinutuzumab

    CLL/SLL criteria: Used in combination with venetoclax and obinutuzumab for histologic transformation (Richter); AND used as additional therapy for partial response, refractory disease, or progression while on prior treatment OR used as first-line for Richter if previously treated for CLL OR used as continuation therapy for complete response until progression

    Prior treatment could have included immune checkpoint inhibitor therapy

    Thymic Carcinoma

    Covered when ALL of the following are met

    Thymic Carcinoma criteria: Used in combination with carboplatin and paclitaxel; AND used as postoperative therapy after R1 or R2 resection OR used as first-line therapy for recurrent, advanced, or metastatic disease

    Per compendia recommended indication

    CLL/SLL (Richter transformation)

    Covered when ALL of the following are met

    CLL/SLL Richter criteria: Used in combination with venetoclax and obinutuzumab for histologic transformation (Richter); AND used as additional therapy for partial response, refractory disease, or progression while on prior treatment OR used as first-line treatment for Richter transformation if previously treated for CLL OR used as continuation therapy for complete response until progression

    Prior treatment could have included PD-1/PD-L1 therapy

    Urothelial Carcinoma (Adjuvant after cystectomy)

    Covered when ALL of the following are met

    Urothelial carcinoma adjuvant criteria: Member has muscle-invasive bladder cancer (MIBC); AND used as a single agent; AND used as adjuvant therapy following cystectomy; AND member has ctDNA MRD as determined by an FDA-approved or CLIA-compliant test

    This is an FDA-approved indication

    Therapy with intravenous atezolizumab (Tecentriq) must not be administered concomitantly with subcutaneous atezolizumab. This is a universal policy exclusion and applies unless a specific indication or exception in the policy states otherwise.

    Prior authorization renewals are only appropriate when the member continues to meet the universal and indication-specific criteria, the original authorization duration has not been exceeded, there is documented disease response (stable disease or tumor decrease), and there is an absence of unacceptable toxicity. If any of these conditions are not met—specifically if the authorization duration has been exceeded, disease progression is documented, or unacceptable toxicity is present—the authorization should not be renewed.

    For this policy excerpt, there are No Medicare Part B covered diagnosis codes listed (stated as N/A for Medicare Part B Covered Diagnosis Codes).

    Billing, Units, and Diagnosis Codes

    Dosing unit limits (HCPCS)HCPCS
    HCPCS unitsMax 120 billable units every 21 days for mesotheliomas, thymic carcinoma, and CLL/SLL; Max 504 billable units every 84 days for all other indications
    HCPCS CodesHCPCSCovered
    J9022Injection, atezolizumab, 10 mg; 1 billable unit = 10 mg
    NDCsNDC
    50242-0917-xxTecentriq 1200 mg/20 mL solution for injection single-dose vial
    50242-0918-xxTecentriq 840 mg/14 mL solution for injection single-dose vial
    Covered ICD-10 Diagnosis Codes (selected excerpt)ICD-10Covered
    C17.0Malignant neoplasm of duodenum
    C17.1Malignant neoplasm of jejunum
    C17.2Malignant neoplasm of ileum
    C17.3Meckel's diverticulum, malignant
    C17.8Malignant neoplasm of overlapping sites of small intestine
    C17.9Malignant neoplasm of small intestine, unspecified
    C18.0Malignant neoplasm of cecum
    C18.2Malignant neoplasm of ascending colon
    C18.3Malignant neoplasm of hepatic flexure
    C18.4Malignant neoplasm of transverse colon
    1–10 of 41
    1/5
    Max units per interval — HCPCS unit limits
    Max units — mesotheliomas, thymic carcinoma, CLL/SLL120 billable units every 21 days
    Max units — all other indications504 billable units every 84 days
    HCPCS unit definitionPolicy units reported as HCPCS billing units per J9022 (10 mg per unit) — see coding section
    Adjuvant / duration thresholds
    Adjuvant duration — NSCLCMay continue up to a maximum of 12 months in members without disease recurrence or unacceptable toxicity
    Adjuvant duration — Urothelial carcinoma (post-cystectomy)

    Authorization, Documentation, and Utilization Management

    Prior Authorization

    Obtain prior authorization (initial validity 6 months)

    Prior authorization is required before initiating atezolizumab; initial approvals are valid for 6 months (180 days). Some indications have maximum cumulative renewal limits (e.g., adjuvant colon and small bowel up to 12 months; NSCLC and urothelial adjuvant up to 12 months; thymic carcinoma up to 24 months; CLL/SLL up to 18 cycles).

    • Initial PA validity: 6 months (180 days).
    • Specified maximum renewal durations apply per indication (see Section I for details).
    Prior Authorization

    Renew PA only when criteria, response, and duration conditions met

    Renewal requests may be granted every 6 months if the member continues to meet universal and indication-specific criteria, the prior authorization duration has not been exceeded, disease response is documented, and there is no unacceptable toxicity.

    • Member must still meet universal and indication-specific criteria (including concomitant therapy/PS requirements).

    Regimens and Dosing Schedules

    Tumor type / settingExample covered regimen(s)Coverage status
    Non‑Small Cell Lung Cancer (NSCLC) — first-line, recurrent/advanced/metastaticAtezolizumab as single agent for PD-L1 ≥50% (TC≥50% or IC≥10%) in PS 0-2; or in combination with carboplatin + pemetrexed; carboplatin + paclitaxel + bevacizumab; or carboplatin + albumin-bound paclitaxel for non-squamous diseasecovered_with_criteria
    Small Cell Lung Cancer (extensive-stage) — first-line or maintenance/subsequentAtezolizumab in combination with carboplatin + etoposide (first-line); maintenance single-agent atezolizumab or in combination with lurbinectedin as specifiedcovered_with_criteria
    Hepatocellular Carcinoma (HCC) — unresectable or metastaticAtezolizumab in combination with bevacizumab (first-line); alternative dosing schedules per regimen guidancecovered_with_criteria
    Cutaneous melanoma (BRAF V600 mutation-positive) — unresectable/metastaticAtezolizumab combined with vemurafenib + cobimetinib (per IMspire150 and policy guidance) with specified lead-in BRAF/MEK dosing prior to atezolizumabcovered_with_criteria
    Colon / Rectal / Small bowel adenocarcinoma (MSI-H/dMMR or POLE/POLD1 ultra-hypermutated) — adjuvant or advancedAtezolizumab following FOLFOX or CAPEOX (adjuvant) followed by single-agent maintenance; single-agent for unresectable/advanced/metastatic diseasecovered_with_criteria
    Peritoneal / pericardial / tunica vaginalis mesothelioma — subsequent therapyAtezolizumab in combination with bevacizumab (subsequent-line)covered_with_criteria
    Cervical cancer (including NECC and other histologies) — first-line or maintenanceAtezolizumab with etoposide + (cisplatin or carboplatin) for small cell NECC; or with bevacizumab + paclitaxel + (cisplatin or carboplatin) for adenocarcinoma/adenosquamous/squamous; maintenance regimens per policycovered_with_criteria
    Thymic carcinoma — postoperative adjuvant or first-line for recurrent/advanced/metastaticAtezolizumab in combination with carboplatin + paclitaxel (postoperative after R1/R2 resection or first-line recurrent/advanced/metastatic)covered_with_criteria
    CLL/SLL — Richter transformation (histologic transformation)Atezolizumab in combination with venetoclax + obinutuzumab as additional, first-line (if previously treated for CLL), or continuation therapy per criteriacovered_with_criteria
    IndicationRegimen / useCoverage status
    Thymic carcinoma — postoperative adjuvant after R1/R2 resectionAtezolizumab in combination with carboplatin and paclitaxel used as postoperative therapy after R1 (microscopic residual) or R2 (macroscopic residual) resectioncovered
    Thymic carcinoma — first-line for recurrent/advanced/metastatic diseaseAtezolizumab in combination with carboplatin and paclitaxel used as first-line therapy for recurrent, advanced, or metastatic diseasecovered
    IndicationCombination regimenCoverage status
    CLL/SLL with histologic (Richter) transformationAtezolizumab in combination with venetoclax and obinutuzumab; may be used as additional therapy for partial response, refractory disease, or progression while on prior treatment; or as first-line for Richter if previously treated for CLL; continuation therapy allowed for complete response until progressioncovered
    Indication groupDosing regimen (IV)Duration / limitsCoverage status
    NSCLC (including adjuvant settings)840 mg every 2 weeks OR 1200 mg every 3 weeks OR 1680 mg every 4 weeks (IV)Adjuvant NSCLC: may continue up to a maximum of 12 months in members without disease recurrence or unacceptable toxicitycovered_with_criteria
    Urothelial carcinoma (adjuvant after cystectomy)1200 mg every 3 weeks OR 1680 mg every 4 weeks (IV)Adjuvant urothelial carcinoma: may continue up to a maximum of 12 months in members without disease recurrence or unacceptable toxicitycovered_with_criteria
    Hepatocellular carcinoma (HCC)840 mg every 2 weeks OR 1200 mg every 3 weeks OR 1680 mg every 4 weeks (IV)Administer until disease progression or unacceptable toxicity (no fixed adjuvant limit specified)covered_with_criteria
    Cutaneous melanoma and other solid tumors840 mg q2w OR 1200 mg q3w OR 1680 mg q4w (regimen selection per tumor type and combination partner)Administer until disease progression or unacceptable toxicity unless indication-specific maximum duration appliescovered_with_criteria
    Thymic carcinoma1200 mg every 3 weeks (IV)Administer intravenously for up to 24 months in absence of disease progression or unacceptable toxicitycovered_with_criteria
    CLL/SLL (Richter transformation)1200 mg every 3 weeks (IV)Administer 1200 mg IV every 3 weeks for up to a total of 18 cyclescovered_with_criteria
    Indication / contextCombination(s) citedNotes / coverage status
    Hepatocellular carcinoma (HCC) — first-line unresectable or metastaticAtezolizumab + bevacizumab (NCCN HEP32 order template referenced)covered_with_criteria
    Cutaneous melanoma (BRAF V600-mutant)Atezolizumab combined with vemurafenib + cobimetinib (IMspire150; referenced literature)covered_with_criteria
    Cervical cancer (metastatic/persistent/recurrent)Atezolizumab combined with bevacizumab + paclitaxel + (cisplatin or carboplatin) or as bevacizumab-containing maintenance after initial therapy (BEATcc trial referenced)covered_with_criteria
    Various trials / tumor typesAtezolizumab combined with chemotherapy regimens or targeted agents per cited trials and NCCN compendia (policy references multiple publications and NCCN templates)mixed

    Line of Therapy Definitions and Mappings

    first-line | second-line | adjuvant

    First-line: Indications specified for first-line use include NSCLC, SCLC, HCC, cutaneous melanoma (BRAF V600 with BRAF/MEK), cervical cancer (first-line combinations), thymic carcinoma; combinations with chemotherapy or targeted agents described
    Subsequent/second-line: Policy allows subsequent-line single-agent or combination therapy for multiple tumor types per indication-specific nodes
    Adjuvant settings listed for NSCLC, colon, small bowel, and urothelial carcinoma with prior chemotherapy and biomarker criteria

    first-line | continuation | adjuvant

    Line assignments in policy: Thymic carcinoma: first-line for recurrent/advanced/metastatic or postoperative after R1/R2; CLL/SLL Richter: first-line if previously treated for CLL, continuation therapy for complete response until progression; Urothelial carcinoma: adjuvant following cystectomy

    Biomarkers, Testing, and Thresholds

    PD-L1 thresholds and testing
    PD-L1 threshold — first-line single-agent NSCLC>=50% (TC >=50% or IC >=10%) for PS 0-2 as determined by FDA-approved or CLIA-compliant test
    PD-L1 threshold — adjuvant single-agent NSCLC>=1% for adjuvant single-agent use after resection and prior adjuvant platinum-based chemotherapy
    PD-L1 assay requirementPD-L1 status must be determined by an FDA-approved or CLIA-compliant test
    MSI-H/dMMR or POLE/POLD1 (ultra-hypermutated)
    MSI-H/dMMR or POLE/POLD1 definitionMSI-H/dMMR or POLE/POLD1 ultra-hypermutated phenotype qualifies for biomarker-defined indications
    POLE/POLD1 example thresholdExample TMB >50 mut/Mb used to characterize POLE/POLD1 ultra-hypermutated tumors

    Definitions and Key Terms

    Atezolizumab (Tecentriq) is an anti–PD-L1 immune checkpoint inhibitor used across a range of solid tumors and select hematologic indications. The policy’s universal criteria require that the member generally has not received prior PD-1/PD-L1–directed therapy unless otherwise specified, and it lists important safety and sequencing considerations that affect coverage decisions.

    Actionable biomarkers (expected for testing)
    Actionable biomarkers listEGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, NRG1, ERBB2 (HER2)
    Testing expectationComplete biomarker testing including molecular assessment via biopsy and/or plasma testing is expected to guide treatment decisions
    Impact on therapy selectionIf a clinically actionable marker is found, it is reasonable to start therapy based on the identified marker; unknown results treated as driver-negative
    MSI-H/dMMR or POLE/POLD1 (biomarker-defined subsets)
    Biomarker-defined subsets
    Policy Summary
    PayerViva Health
    PolicyTecentriq (atezolizumab) — Coverage and Authorization Policy
    Policy CodePolicy IC-0278
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial validity 6 months) and provide documentation showing indication-specific criteria, disease response, and absence of unacceptable toxicity.
    SourceLink
    On This Page
    Coverage Criteria by IndicationBilling, Units, and Diagnosis CodesAuthorization, Documentation, and Utilization ManagementRegimens and Dosing SchedulesLine of Therapy Definitions and MappingsBiomarkers, Testing, and ThresholdsDefinitions and Key Terms
    Adjuvant single-agent use up to a maximum of 12 months
    Thymic carcinoma durationAdminister intravenously for up to 24 months in absence of disease progression or unacceptable toxicity
    CLL/SLL (Richter) durationAdminister 1200 mg IV every 3 weeks for up to a total of 18 cycles
  1. Duration of authorization must not have been exceeded (refer to Section I).
  2. Documented disease response (stable disease or tumor decrease) and absence of unacceptable toxicity required.
  3. Prior Authorization

    PA may be required due to indication and drug cost (NQTL)

    Prior authorization is applied based on Non‑Quantitative Treatment Limitation (NQTL) factors; the policy identifies indication and cost of the drug as considerations when implementing PA requirements.

    • NQTL checklist lists Indication = Yes (consider for PA).
    • Cost of drug = Yes (consider for PA).
    Step Therapy

    Adhere to indication-specific clinical sequencing and combinations

    Follow the policy-specified sequencing for indications — e.g., NSCLC and SCLC specify first‑line, subsequent, or maintenance settings and permitted combinations with chemotherapy or targeted agents as conditions for coverage.

    • NSCLC: first-line single-agent or combination regimens and adjuvant settings tied to PD-L1/biomarker and PS criteria.
    • SCLC: first-line with carboplatin+etoposide, maintenance after first-line atezolizumab+carboplatin+etoposide, or subsequent therapy per policy.
    Step Therapy

    Use atezolizumab only with specified combination in CLL/SLL (Richter)

    For CLL/SLL with Richter transformation, use of atezolizumab is specified only in combination with venetoclax and obinutuzumab; prior therapies including immune checkpoint inhibitors may be part of the member's history and are noted in sequencing.

    • Atezolizumab must be used in combination with venetoclax and obinutuzumab for histologic transformation (Richter).
    • Prior treatment could have included immune checkpoint inhibitor therapy.
    Note

    Utilization management applied per NQTL checklist

    Utilization management (including prior authorization) was applied using the NQTL checklist and is intended to be comparable across drug benefits; the checklist documents factors considered in designing PA.

    • Appendix A states utilization management NQTL applies comparably to MH/SUD and M/S drug benefits.
    • Checklist indicates which factors (e.g., indication, cost) were considered in applying PA.
    Documentation Required

    Provide complete actionable biomarker testing (biopsy and/or plasma)

    Document complete biomarker testing results to support treatment decisions and authorization: testing should include EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, NRG1, and ERBB2 (HER2) via biopsy and/or plasma.

    • Complete molecular assessment of EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, NRG1, ERBB2 (HER2) is expected.
    • If an actionable marker is found, treatment may be guided by that result; if unknown, treat as though driver oncogenes are absent.
    Documentation Required

    Submit indication-specific clinical documentation for authorization and renewals

    Include indication-specific supporting documentation with initial authorization and renewal requests — for example, evidence of muscle‑invasive bladder cancer and ctDNA MRD status for adjuvant urothelial carcinoma, documentation of continued meeting of criteria, disease response, and absence of unacceptable toxicity.

    • For urothelial adjuvant use: submit ctDNA MRD results from an FDA‑approved or CLIA‑compliant test.
    • For renewals: provide documentation of continued eligibility, disease stabilization or tumor decrease, and absence of unacceptable toxicity (see examples).
    Note

    Follow CMS NCDs/LCDs/LCAs for Medicare members

    For Medicare beneficiaries, ensure compliance with applicable CMS coverage determinations: follow National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) where applicable.

    • Medicare coverage for Part B drugs is governed by CMS manuals; search the Medicare Coverage Database for applicable NCDs/LCDs/LCAs.
    • Plan may apply additional indications at its discretion but CMS determinations must be followed when applicable.
    Denial Risk

    Verify no prior PD‑1/PD‑L1 therapy unless exception applies

    Do not initiate or continue therapy for members who have received prior PD‑1/PD‑L1‑directed therapy unless the policy or indication specifically allows it — prior PD‑1/PD‑L1 therapy may violate the universal criterion and render the request ineligible.

    • Universal criteria state member has not received previous PD‑1/PD‑L1‑directed therapy unless otherwise specified.
    • Exceptions are noted only where the policy explicitly permits prior PD‑1/PD‑L1 therapy.
    Denial Risk

    Expect denials/non‑renewal for exceeded duration, progression, or unacceptable toxicity

    Renewal requests may be denied or not renewed if the authorization duration has been exceeded, disease progression is documented, or unacceptable toxicity from atezolizumab is present (examples include serious immune‑mediated adverse reactions, severe infusion reactions, or HSCT complications).

    • Authorization duration must not be exceeded (see Section I for limits).
    • Documented disease progression or unacceptable toxicity (listed examples) are grounds for denial or non‑renewal.
    Prior Authorization

    Be prepared to justify PA based on indication and drug cost (NQTL)

    The NQTL checklist identifies 'Cost of drug' and 'Indication' as drivers considered for prior authorization; include cost/indication justification as needed for PA submission.

    • Appendix A lists Indication = Yes and Cost of drug = Yes for consideration in PA design.
    • Use the policy’s indication-based criteria in the submission to address these NQTL considerations.

    Policy specifies line-of-therapy roles per indication

    Assay requirementBiomarker status to be determined by an FDA-approved or CLIA-compliant test
    BRAF V600
    BRAF V600 biomarkerBRAF V600 mutation-positive status required for atezolizumab use in combination with cobimetinib and vemurafenib for cutaneous melanoma
    Test requirementMutation must be detected by an FDA-approved or CLIA-compliant test
    Line of therapyUsed as first-line or subsequent therapy for unresectable or metastatic disease per policy
    ctDNA MRD (adjuvant urothelial carcinoma)
    ctDNA MRD positivity requirementPositive circulating tumor DNA (ctDNA) molecular residual disease (MRD) as determined by an FDA-approved or CLIA-compliant test is required for adjuvant use in muscle-invasive bladder cancer following cystectomy
    Assay sourceIf confirmed using an FDA-approved assay, see FDA companion diagnostics listings
    Use contextRequired specifically for adjuvant single-agent atezolizumab post-cystectomy (FDA-approved indication)
    ctDNA — general references and requirements
    ctDNA general referencectDNA is used to determine MRD status to guide adjuvant atezolizumab in urothelial carcinoma and is referenced in policy clinical contexts
    Assay requirementctDNA/ MRD status must be determined by an FDA-approved or CLIA-compliant test
    DocumentationDocumentation of ctDNA MRD status should be provided with authorization requests and renewals where required
    MSI-H/dMMR or POLE/POLD1 ultra-hypermutated tumors define eligibility for colon, rectal, and small bowel indications
    TMB examplePOLE/POLD1 ultra-hypermutated phenotype example: TMB >50 mut/Mb
    Assay requirementStatus must be determined by an FDA-approved or CLIA-compliant test
    ctDNA MRD — definition and test requirements
    ctDNA MRD definitionCirculating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-approved or CLIA-compliant test
    Use for authorizationRequired documentation of ctDNA MRD status is necessary for adjuvant urothelial carcinoma authorization and renewal
    FDA assay linkageIf confirmed using an FDA-approved assay, see FDA companion diagnostics listing
    Unacceptable toxicity — serious immune-mediated adverse reactions
    Unacceptable toxicity — examplesImmune-mediated adverse reactions (e.g., pneumonitis, hepatitis, colitis, endocrinopathies, nephritis/renal dysfunction), severe infusion reactions, complications of allogeneic HSCT, solid organ transplant rejection
    Dermatologic examplesSevere dermatologic reactions including Stevens-Johnson syndrome (SJS), DRESS, and TEN listed among examples
    Renewal implicationPresence of unacceptable toxicity is a reason to deny renewal or discontinue therapy
    NCCN Guidelines and other compendia references
    NCCN Guidelines/Compendia citedNational Comprehensive Cancer Network clinical practice guidelines and NCCN Drugs & Biologics Compendium (2026) referenced as sources for indications and order templates
    Specific NCCN templateAtezolizumab + Bevacizumab: Hepatocellular Carcinoma Order Template, HEP32 (2026) referenced
    Other referencesPolicy also cites FDA package insert and peer-reviewed literature supporting indications